VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 164 filers reported holding VERVE THERAPEUTICS INC in Q1 2024. The put-call ratio across all filers is 1.41 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $873,054 | -0.4% | 65,742 | +4.6% | 0.00% | 0.0% |
| Q4 2023 | $876,171 | +33.1% | 62,853 | +26.6% | 0.00% | 0.0% |
| Q3 2023 | $658,452 | -35.4% | 49,657 | -8.6% | 0.00% | 0.0% |
| Q2 2023 | $1,018,987 | +83.3% | 54,346 | +41.0% | 0.00% | 0.0% |
| Q1 2023 | $555,833 | -21.7% | 38,546 | +5.0% | 0.00% | 0.0% |
| Q4 2022 | $710,243 | -27.8% | 36,705 | +28.1% | 0.00% | 0.0% |
| Q3 2022 | $984,000 | +415.2% | 28,644 | +128.5% | 0.00% | – |
| Q2 2022 | $191,000 | -30.8% | 12,533 | +3.4% | 0.00% | – |
| Q1 2022 | $276,000 | -31.3% | 12,121 | +11.5% | 0.00% | – |
| Q4 2021 | $402,000 | – | 10,870 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,008,809 | $37,665,169 | 23.26% |
| Alphabet Inc. | 10,549,086 | $197,795,362 | 10.63% |
| Casdin Capital, LLC | 2,360,571 | $44,260,706 | 3.87% |
| MPM BioImpact LLC | 857,940 | $16,086,375 | 3.24% |
| Redmile Group, LLC | 1,061,960 | $19,911,750 | 0.76% |
| Novo Holdings A/S | 500,000 | $9,375,000 | 0.72% |
| ARK Investment Management | 5,150,851 | $96,578,455 | 0.64% |
| Avidity Partners Management LP | 878,600 | $16,473,750 | 0.58% |
| Nikko Asset Management Americas, Inc. | 2,185,857 | $40,941,102 | 0.43% |
| Cormorant Asset Management, LP | 350,000 | $6,562,500 | 0.37% |